rofecoxib has been researched along with Melanoma in 5 studies
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 9.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| " Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells." | 7.96 | Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. ( Buzharevski, A; Hey-Hawkins, E; Laube, M; Lönnecke, P; Maksimović-Ivanić, D; Mijatović, S; Murganić, B; Neumann, W; Paskaš, S; Pietzsch, J; Sárosi, MB, 2020) |
| "A Phase II trial was initiated to analyze the activity of a continuously administered molecularly targeted treatment regimen (daily pioglitazone [45 mg administered orally] and rofecoxib [25 mg administered orally]) combined with sequentially added angiostatic chemotherapy for patients with previously treated metastatic melanoma (n = 19) or soft tissue sarcoma (n = 21)." | 7.72 | Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. ( Andreesen, R; Bataille, F; Berand, A; Bross, K; Krause, SW; Reichle, A; Vogt, T; Wild, P, 2004) |
| "The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced melanoma patients." | 5.10 | Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. ( Gille, J; Kaufmann, R; Spieth, K, 2003) |
| " Herein, we report the synthesis of carborane-containing derivatives of rofecoxib that display remarkable cytotoxic or cytostatic activity in the micromolar range with excellent selectivity for melanoma and colon cancer cell lines over normal cells." | 3.96 | Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells. ( Buzharevski, A; Hey-Hawkins, E; Laube, M; Lönnecke, P; Maksimović-Ivanić, D; Mijatović, S; Murganić, B; Neumann, W; Paskaš, S; Pietzsch, J; Sárosi, MB, 2020) |
| " Here we report on a patient with a metastatic melanoma of the leg who experienced a complete and sustained regression of skin metastases upon continuous single treatment with the cyclooxygenase-2 inhibitor rofecoxib." | 3.73 | Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. ( Lejeune, FJ; Monnier, Y; Rüegg, C, 2006) |
| "A Phase II trial was initiated to analyze the activity of a continuously administered molecularly targeted treatment regimen (daily pioglitazone [45 mg administered orally] and rofecoxib [25 mg administered orally]) combined with sequentially added angiostatic chemotherapy for patients with previously treated metastatic melanoma (n = 19) or soft tissue sarcoma (n = 21)." | 3.72 | Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. ( Andreesen, R; Bataille, F; Berand, A; Bross, K; Krause, SW; Reichle, A; Vogt, T; Wild, P, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buzharevski, A | 1 |
| Paskaš, S | 1 |
| Sárosi, MB | 1 |
| Laube, M | 1 |
| Lönnecke, P | 1 |
| Neumann, W | 1 |
| Murganić, B | 1 |
| Mijatović, S | 1 |
| Maksimović-Ivanić, D | 1 |
| Pietzsch, J | 1 |
| Hey-Hawkins, E | 1 |
| Spieth, K | 1 |
| Kaufmann, R | 1 |
| Gille, J | 1 |
| Reichle, A | 2 |
| Bross, K | 1 |
| Vogt, T | 2 |
| Bataille, F | 1 |
| Wild, P | 1 |
| Berand, A | 2 |
| Krause, SW | 1 |
| Andreesen, R | 2 |
| Lejeune, FJ | 1 |
| Monnier, Y | 1 |
| Rüegg, C | 1 |
| Coras, B | 1 |
| Terheyden, P | 1 |
| Neuber, K | 1 |
| Trefzer, U | 1 |
| Schultz, E | 1 |
| Bröcker, EB | 1 |
| Landthaler, M | 1 |
2 trials available for rofecoxib and Melanoma
| Article | Year |
|---|---|
Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Apoptosis; Busulfan; Cell Division; Cell Survival; C | 2003 |
Targeted combined anti-inflammatory and angiostatic therapy in advanced melanoma: a randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Che | 2007 |
3 other studies available for rofecoxib and Melanoma
| Article | Year |
|---|---|
Carboranyl Derivatives of Rofecoxib with Cytostatic Activity against Human Melanoma and Colon Cancer Cells.
Topics: Antineoplastic Agents; Boron Compounds; Carcinogenesis; Cell Line, Tumor; Colonic Neoplasms; Cycloox | 2020 |
Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2004 |
Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor.
Topics: Aged; Cyclooxygenase 2 Inhibitors; Female; Humans; Lactones; Melanoma; Remission Induction; Skin Neo | 2006 |